Contribution of alcohol use disorders on the burden of chronic hepatitis C in France, 2008–2013: A nationwide retrospective cohort study

Journal of Hepatology

Volumn 67, Issue 3, 2017, Pages 454-461

  Schwarzinger, Michaël ^a,b   Baillot, Sylvain ^a   Yazdanpanah, Yazdan ^b,c   Rehm, Jürgen ^d,e,f,g   Mallet, Vincent ^h,i,j  

^a Translational Health Economics Network   (France)

^b UNIVERSITÉ PARIS DIDEROT   (France)

^c BICHAT HOSPITAL   (France)

^d CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^h UNIVERSITÉ PARIS DESCARTES   (France)

ⁱ INSERM   (France)

^j ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

more..

Author keywords

Alcohol use disorders; Burden of disease; Chronic hepatitis C; Cirrhosis; Disease progression; End stage liver disease; Hepatocellular carcinoma; Mortality; Natural history; Prognosis

Indexed keywords

ADULT; AGED; ALCOHOL ABSTINENCE; ALCOHOL REHABILITATION; ALCOHOLISM; ARTICLE; ATTRIBUTABLE RISK; CHRONIC HEPATITIS C; COHORT ANALYSIS; COMORBIDITY; DECOMPENSATED LIVER CIRRHOSIS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; FRANCE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HOSPITAL ADMISSION; HOSPITAL MORTALITY; HUMAN; ICD-10; INFECTION RISK; LENGTH OF STAY; LIVER CANCER; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; METABOLIC SYNDROME X; MIXED INFECTION; NONHUMAN; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK REDUCTION; VIRUS TRANSMISSION; COMPLICATION; DISEASE EXACERBATION; MIDDLE AGED; MORTALITY; TIME FACTOR;

ADULT; ALCOHOLISM; DISEASE PROGRESSION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 85020098060     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2017.03.031     Document Type: Article

References (37)

1. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388 (2016), 1459–1544.
2. Webster, D.P., Klenerman, P., Dusheiko, G.M., Hepatitis C. Lancet 385 (2015), 1124–1135.
3. Najafzadeh, M., Andersson, K., Shrank, W.H., Krumme, A.A., Matlin, O.S., Brennan, T., et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med 162 (2015), 407–419.
4. Innes, H.A., McDonald, S.A., Dillon, J.F., Allen, S., Hayes, P.C., Goldberg, D., et al. Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes. Hepatology 62 (2015), 355–364.
5. Armstrong, G.L., Wasley, A., Simard, E.P., McQuillan, G.M., Kuhnert, W.L., Alter, M.J., The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 144 (2006), 705–714.
6. Rosman, A.S., Waraich, A., Galvin, K., Casiano, J., Paronetto, F., Lieber, C.S., Alcoholism is associated with hepatitis C but not hepatitis B in an urban population. Am J Gastroenterol 91 (1996), 498–505.
7. Roudot-Thoraval, F., Bastie, A., Pawlotsky, J.M., Dhumeaux, D., Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus. Hepatology 26 (1997), 485–490.
8. Delarocque-Astagneau, E., Roudot-Thoraval, F., Campese, C., Desenclos, J.C., Past excessive alcohol consumption: a major determinant of severe liver disease among newly referred hepatitis C virus infected patients in hepatology reference centers, France, 2001. Ann Epidemiol 15 (2005), 551–557.
9. Marcellin, P., Pequignot, F., Delarocque-Astagneau, E., Zarski, J.P., Ganne, N., Hillon, P., et al. Mortality related to chronic hepatitis B and chronic hepatitis C in France: Evidence for the role of HIV coinfection and alcohol consumption. J Hepatol 48 (2008), 200–207.
10. Koretz, R.L., Lin, K.W., Ioannidis, J.P.A., Lenzer, J., Is widespread screening for hepatitis C justified?. BMJ, 350, 2015, 4.
11. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Teo C-G, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recommendations and reports: Morbidity and mortality weekly report Recommendations and reports/Centers for Disease Control. 2012;61(RR-4):1–32.
12. Agence Technique de l'Information sur l'Hospitalisation. Aide à l'utilisation des informations de chaînage [How to use de-identified patient information] Lyon, France: Agence technique de l'information sur l'hospitalisation,; 2014 [updated October 6, 2015. Available from: http://www.atih.sante.fr/aide-lutilisation-des-informations-de-chainage.
13. Rehm, J., Mathers, C., Popova, S., Thavorncharoensap, M., Teerawattananon, Y., Patra, J., Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet 373 (2009), 2223–2233.
14. Stanaway, J.D., Flaxman, A.D., Naghavi, M., Fitzmaurice, C., Vos, T., Abubakar, I., et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet 388 (2016), 1081–1088.
15. Poynard, T., Bedossa, P., Opolon, P., Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349 (1997), 825–832.
16. Askgaard, G., Gronbaek, M., Kjaer, M.S., Tjonneland, A., Tolstrup, J.S., Alcohol drinking pattern and risk of alcoholic liver cirrhosis: a prospective cohort study. J Hepatol 62 (2015), 1061–1067.
17. Seeff, L.B., Miller, R.N., Rabkin, C.S., Buskell-Bales, Z., Straley-Eason, K.D., Smoak, B.L., et al. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 132 (2000), 105–111.
18. Wiese, M., Fischer, J., Lobermann, M., Gobel, U., Grungreiff, K., Guthoff, W., et al. Evaluation of liver disease progression in the German hepatitis C virus (1b)-contaminated anti-D cohort at 35 years after infection. Hepatology 59 (2014), 49–57.
19. Nelson, P.K., Mathers, B.M., Cowie, B., Hagan, H., Des Jarlais, D., Horyniak, D., et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 378 (2011), 571–583.
20. Butt, A.A., Yan, P., Lo Re, V. 3rd, Rimland, D., Goetz, M.B., Leaf, D., et al. Liver fibrosis progression in hepatitis C virus infection after seroconversion. JAMA Intern Med 175 (2015), 178–185.
21. Donato, F., Tagger, A., Gelatti, U., Parrinello, G., Boffetta, P., Albertini, A., et al. Alcohol and hepatocellular carcinoma: The effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 155 (2002), 323–331.
22. Baliunas, D.O., Taylor, B.J., Irving, H., Roerecke, M., Patra, J., Mohapatra, S., et al. Alcohol as a risk factor for type 2 diabetes: A systematic review and meta-analysis. Diabetes Care 32 (2009), 2123–2132.
23. Beulens, J.W.J., van der Schouw, Y.T., Bergmann, M.M., Rohrmann, S., Schulze, M.B., Buijsse, B., et al. Alcohol consumption and risk of type 2 diabetes in European men and women: influence of beverage type and body size The EPIC-InterAct study. J Intern Med 272 (2012), 358–370.
24. Mallet, V., Hamed, K., Schwarzinger, M., Prognosis of patients with chronic hepatitis B in France (2008–2013): A nationwide, observational and hospital-based study. J Hepatol 66 (2017), 514–520.
25. Razavi, H., Estes, C., Pasini, K., Gower, E., Hindman, S., HCV treatment rate in select European countries in 2004–2010. J Hepatol 58 (2013), S22–S23.
26. Deuffic-Burban, S., Deltenre, P., Buti, M., Stroffolini, T., Parkes, J., Muhlberger, N., et al. Predicted effects of treatment for HCV infection vary among European countries. Gastroenterology 143 (2012), 974–985 e14.
27. van der Meer, A.J., Wedemeyer, H., Feld, J.J., Dufour, J.F., Zeuzem, S., Hansen, B.E., et al. Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population. JAMA 312 (2014), 1927–1928.
28. Vandenbulcke, H., Moreno, C., Colle, I., Knebel, J.F., Francque, S., Serste, T., et al. Alcohol intake increases the risk of HCC in hepatitis C virus-related compensated cirrhosis: A prospective study. J Hepatol 65 (2016), 543–551.
29. Falck-Ytter, Y., Kale, H., Mullen, K.D., Sarbah, S.A., Sorescu, L., McCullough, A.J., Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 136 (2002), 288–292.
30. Kenny-Walsh, E., Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 340 (1999), 1228–1233.
31. Case, A., Deaton, A., Rising morbidity and mortality in midlife among white non-Hispanic Americans in the 21st century. Proc Natl Acad Sci U S A 112 (2015), 15078–15083.
32. Kochanek, K.D., Murphy, S.L., Xu, J., Tejada-Vera, B., Deaths: final data for 2014. Natl Vital Stat Rep 65 (2016), 1–122.
33. Shiels, M.S., Chernyavskiy, P., Anderson, W.F., Best, A.F., Haozous, E.A., Hartge, P., et al. To 2014: an analysis of death certificate data. Lancet, 2017, 1999, 10.1016/s0140-6736(17)30187-3.
34. Conti, F., Buonfiglioli, F., Scuteri, A., Crespi, C., Bolondi, L., Caraceni, P., et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol 65 (2016), 727–733.
35. Rehm, J., Shield, K.D., Gmel, G., Rehm, M.X., Frick, U., Modeling the impact of alcohol dependence on mortality burden and the effect of available treatment interventions in the European Union. Eur Neuropsychopharmacol 23 (2013), 89–97.
36. Global Action Plan for the Prevention and Control of NCDs 2013-2020 Geneva: World Health Organization; 2013 [Available from: http://www.who.int/iris/bitstream/10665/94384/1/9789241506236_eng.pdf.
37. Rehm, J., Lachenmeier, D.W., Llopis, E.J., Imtiaz, S., Anderson, P., Evidence of reducing ethanol content in beverages to reduce harmful use of alcohol. Lancet Gastroenterol Hepatol 1 (2016), 78–83.